Phase 2 data point to the promising efficacy of adding ipilimumab to neoadjuvant nivolumab plus chemotherapy in people with operable non-small-cell lung cancer.

Patients with localized renal cell carcinoma at high risk for recurrence do not derive a significant disease-free survival benefit from the postoperative use of nivolumab plus ipilimumab versus placebo, shows the phase 3 CheckMate 914 study.

A pooled analysis of clinical trial data points to a link between obesity and an increased risk for any-grade immune-related adverse events among people receiving nivolumab monotherapy for advanced cancer.

Data from a pooled analysis of studies investigating first-line nivolumab plus ipilimumab has shown that, in line with the original trials, the combination is well tolerated by people with metastatic non-small-cell lung cancer.

Statins appear to be associated with improved outcomes among patients with metastatic renal cell carcinoma taking nivolumab, indicates a chart review.

The addition of nivolumab to neoadjuvant chemotherapy significantly improves the progression-free survival and overall survival of individuals with resectable stage IIIA–B non-small-cell lung cancer, suggest data from NADIM II.

The latest findings from the CheckMate 9ER trial show that the combination of nivolumab plus cabozantinib continues to offer superior survival to that of sunitinib for patients with treatment-naïve advanced renal cell carcinoma after a median follow-up of 32.9 months.

The neoadjuvant combination of nivolumab and chemotherapy elicits a significantly higher pathologic complete response rate than chemotherapy alone in people with resectable stage IIIA–B non-small-cell lung cancer, shows the phase 2 NADIM II study.

Median OS for nivolumab>cabozantinib sequence versus cabozantinib > nivolumab was 28.8 versus 19.9 months ( p  = 0.2); median PFS for both the sequences were similar at 5.7 months.

Neoadjuvant treatment with nivolumab plus chemotherapy achieves significantly better event-free survival than chemotherapy alone, suggests the CheckMate 816 trial of patients with resectable non-small-cell lung cancer.

medwireNews: Patients with resectable, early-stage non-small-cell lung cancer (NSCLC) may be given nivolumab with platinum-doublet chemotherapy prior to surgery, the US FDA has announced .

medwireNews : The EMA recommends expanding the indication for nivolumab monotherapy  to include the adjuvant treatment of PD-L1-positive, high-risk muscle-invasive urothelial carcinoma (MIUC).

Combination treatment with nivolumab plus axitinib has achieved a high response rate in patients with metastatic renal cell carcinoma enrolled in a phase 1/2 trial.

People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma report less decline in health-related quality of life during treatment than those given sunitinib, show data from the phase 3 CheckMate 9ER trial.

The median DFS times in the nivolumab and placebo groups were 20.8 and 10.8 months, respectively.

Adding nivolumab to carboplatin, paclitaxel, and bevacizumab significantly prolongs progression-free survival in people with advanced nonsquamous non-small-cell lung cancer without sensitizing mutations, research shows.

The addition of ipilimumab to nivolumab does not improve the survival outcomes of patients with advanced squamous non-small-cell cancer who have previously received chemotherapy, shows the phase 3 LUNG-MAP S1400I trial.

Adding nivolumab to neoadjuvant chemotherapy for resectable non-small-cell lung cancer is not associated with surgical delays or complications, show CheckMate 816 data presented at the 2021 ASCO Annual Meeting.

The combination of bipolar androgen therapy and nivolumab elicits responses and is well tolerated by men with metastatic castration-resistant prostate cancer, indicate phase 2 findings.

Patients with at least two sites of metastatic RCC were randomly assigned to receive four cycles of nivolumab plus ipilimumab therapy every 3 weeks followed by monthly nivolumab maintenance, given with or without CBM-588 as an 80 mg oral supplement twice daily.